Trial Profile
A phase I/II trial of an encapsulated cell therapy product [NovaCaps] for advanced, inoperable pancreatic cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Apr 2016
Price :
$35
*
At a glance
- Drugs Microencapsulated CYP2B1-expressing cells+ifosfamide PharmaCyte Biotech (Primary) ; Ifosfamide
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Apr 2016 Results published in the PharmaCyte Biotech Media Release
- 21 Jul 2015 Results published in PharmaCyte Biotech media release.
- 10 Jun 2011 New trial record